Journal of Blood Medicine
Volume 12, 2021 - Issue
Open access
189
Views
8
CrossRef citations to date
0
Altmetric
Original Research
Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials
Robert Klamroth1 Department of Internal Medicine, Hemophilia Treatment Centre, Vivantes Klinikum im Friedrichshain, Berlin, GermanyCorrespondence[email protected]
https://orcid.org/0000-0003-4194-8183
Piotr Wojciechowski2 Creativ-Ceutical, Krakow, Poland
, Samuel Aballéa3 Creativ-Ceutical, Rotterdam, the Netherlands
, Françoise Diamand4 Creativ-Ceutical, Paris, France
, Zalmai Hakimi5 Health Economics and Outcomes Research (Global), Sobi, Stockholm, Sweden
, Jameel Nazir5 Health Economics and Outcomes Research (Global), Sobi, Stockholm, Sweden
, Lydia Abad-Franch6 Global Medical Affairs Hematology, Sobi, Stockholm, Sweden
, Stefan Lethagen7 Medical and Clinical Sciences, Sobi, Stockholm, Sweden
, Elena Santagostino8 Medical Affairs Hematology, Sobi, Stockholm, Sweden
& Michael D Tarantino9 The Bleeding and Clotting Disorders Institute, University of Illinois College of Medicine-Peoria, Peoria, IL, USA
show all
Pages 115-122
|
Published online: 25 Feb 2021
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.